enGene Holdings Inc.
ENGNNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for ENGN. That does not mean none is planned.
Get an email about ENGN's next catalysts
Track enGene Holdings (ENGN) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
2 upcoming events in our data (earnings, regulatory event).See the timeline
2 upcoming, 0 past
ENGN Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.48 | FQ end Oct/2026 | Call: tbd
Regulatory — Detalimogene
For Bladder Cancer. enGene targets 2027 approval for detalimogene in bladder cancer. The company is aiming to address an expanding market opportunity in the bladder cancer space.
SourceMarket Overview
Stock performance and key metrics
EG-70 (phase 1)
Superficial Bladder Cancer
EG-70 (phase 2) Master Protocol
Superficial Bladder Cancer
Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
Superficial Bladder Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
EG-70 (phase 1) | Phase 2 | Superficial Bladder Cancer | - | - |
EG-70 (phase 2) Master Protocol | Phase 2 | Superficial Bladder Cancer | - | - |
Surfactant Bladder Pre-Rinse and EG-70 (Substudy) | Phase 2 | Superficial Bladder Cancer | - | - |
Frequently asked questions
What is in enGene Holdings Inc.'s drug pipeline?→
CatalystAlert tracks 3 drug candidates in enGene Holdings Inc.'s (ENGN) pipeline across Phase 2. Its lead program is EG-70 (phase 1) (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is enGene Holdings Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for enGene Holdings Inc. (ENGN) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track ENGN biotech catalysts?→
Add ENGN to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow enGene Holdings Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.